2-Arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: Synthesis, binding studies and behavioral efficacy

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 3997-4000

  Dubowchik, Gene M ^a   Michne, Jodi A ^a   Zuev, Dmitry ^a   Schwartz, Wendy ^a   Scola, Paul M ^a   James, Clint A ^a   Ruediger, Edward H ^a   Pin, Sokhom S ^a   Burris, Kevin D ^a,b   Balanda, Lynn A ^a   Gao, Qi ^a   Wu, Dedong ^a   Fung, Lawrence ^a,c   Fiedler, Tracey ^a   Browman, Kaitlin E ^a,d   Taber, Matthew T ^a   Zhang, Jie ^a,e  

^a BRISTOL MYERS SQUIBB   (United States)

^b Palatin Technologies Inc   (United States)

^c NEUROGEN CORPORATION   (United States)

^d ABBOTT LABORATORIES   (United States)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARYLAMINO 4 TRIFLUOROMETHYL 5 AMINOMETHYLTHIAZOLE; BUSPIRONE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG UPTAKE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TRANQUILIZING ACTIVITY;

EID: 10744224681     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.08.055     Document Type: Article

References (21)

1. Owens M.J., Nemeroff C.B. Pharmacol. Rev. 43:1991;425.
2. Grigoriadis D.E., Haddach M., Ling N., Saunders J. Curr. Med. Chem. CNS Agents. 1:2001;63.
3. Plotsky P.M. J. Neuroendocrinol. 3:1991;1.
4. Kasckow J.W., Baker D., Geracioti T.D. Peptides. 22:2001;845.
5. Holsboer F.J. Psychiatric Res. 33:1999;181.
6. Banki C.M., Karmasci L., Bissette G., Nemeroff C.B. Eur. Neuropsychopharmacol. 2:1992;107.
7. Webster E.L., Torpy D.J., Elenkov I.J., Chrousos G.P. Ann. N.Y. Acad. Sci. 840:1998;21.
8. Takahashi L.K. Neurosci. Behav. Rev. 25:2001;627.
9. Gilligan P.J., Robertson D.W., Zaczek R. J. Med. Chem. 43:2000;1641.
10. McCarthy, J. R.; Heinrichs, C.; Grigoriadis, D. E. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic: San Diego, CA, 1999; Vol. 34, p 11.
11. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley F.D. 3rd, Winston E.N., Chen Y.L., Heym J. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10477.
12. Chen C., Dagnino R., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.I., Liu Z., Moran T., Webb T.R., Whitten J.P., Xie Y.F., McCarthy J.R. J. Med. Chem. 39:1996;4358.
13. Dodson R.M., King L.C. J. Am. Chem. Soc. 67:1945;2242.
14. Levin J.I., Turos E., Weinreb S.M. Synth. Commun. 12:1982;989.
15. 17.
16. Dieterich K.D., DeSouza E.B. Brain Res. 733:1996;113.
17. Suman-Chauhan N., Carnell P., Franks R., Webdale L., Gee N.S., McNulty S., Rossant C.J., Van Leeuwen D., MacKenzie R., Hall M.D. Eur. J. Pharmacol. 379:1999;219.
18. Wilde, R. G.; Klaczkiewicz, J. D.; Carter, K. L.; Gilligan, P. J.; Olson, R. E.; Frietze, W. E.; Buckner, W. H.; Curry, M. A.; Robertson, D. W.; Sun, J. H.; Arneric, S. P.; Hartig, P.; Fitzgerald, L. W.; Marshal, W. J. 219th ACS National Meeting, San Francisco, CA, 2000; MEDI 317.
19. 3: C 42.45, H 3.96, N 8.25. Found: C 42.56, H 3.94, N 8.07.
20. Synthesis of 9 (yields are unoptimized):
21. Grewal S.S., Shepherd J.K., Bill D.J., Fletcher A., Dourish C.T. Psychopharmacology. 133:1997;29.